2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
118
Neoplasms
110
Lung Neoplasms
65
Colorectal Neoplasms
52
Prostatic Neoplasms
46
Carcinoma, Non-Small-Cell Lung
46
Pancreatic Neoplasms
34
Melanoma
33
Ovarian Neoplasms
29
Neoplastic Cells, Circulating
29
Head and Neck Neoplasms
27
Uterine Cervical Neoplasms
23
Multiple Myeloma
20
Glioma
20
Colonic Neoplasms
20
Sarcoma
19
Carcinoma, Hepatocellular
19
Leukemia, Myeloid, Acute
18
Neoplasm Metastasis
17
Lymphoma
15
Glioblastoma
15
Esophageal Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Hematologic Neoplasms
14
Leukemia
13
Endometrial Neoplasms
13
Myelodysplastic Syndromes
11
Kidney Neoplasms
11
Gastrointestinal Neoplasms
11
Carcinoma, Renal Cell
11
Interventions
Abiraterone Acetate
7
enzalutamide
6
olaparib
5
Prednisone
5
Pluvicto
5
Docetaxel
5
radium Ra 223 dichloride
4
darolutamide
4
cabazitaxel
3
Prednisolone
3
testosterone 17 beta-cypionate
2
fludarabine
2
abiraterone
2
Nivolumab
2
Cyclophosphamide
2
Androgen Antagonists
2
sipuleucel-T
1
rucaparib
1
poly ICLC
1
pamiparib
1
niraparib
1
lactitol
1
fludarabine phosphate
1
fluciclovine F-18
1
enfortumab vedotin
1
ebastine
1
copanlisib
1
cabozantinib
1
bempegaldesleukin
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Blood Specimen Collection
×
Clear all
NCT06492122
2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1
Recruiting
50 enrolled